Merck KGaA Collaborates with Personalis to Develop Novel Biomarkers for Cancer Therapies

Merck KGaA Collaborates with Personalis to Develop Novel Biomarkers for Cancer Therapies

Shots:

  • Merck KGaA to utilize Personalis’ cancer immunogenomics platform, ImmunoID NeXT to evaluate novel biomarkers and mechanisms of resistance to cancer therapies
  • The collaboration leads to the development of novel biomarker identification, analysis of therapy resistance mechanisms, patient stratification, combination therapy strategy and molecular categorization of cancer indications for enabling precision therapy
  • Personalis’ ImmunoID NeXT is an end-to-end solution for the discovery of precision oncology biomarkers via clinical applications.  It combines the pioneering NeXT assay, sophisticated analytical engines, and quality support providing researchers with the immunogenomic data needed to drive the programs

Click here to­ read full press release/ article | Ref: Business wire | Image: Yahoo Finance